Todas las investigaciones
ReclutamientoFASE3INTERVENCIONISTA

A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease

Fabry disease is a rare genetic condition where the body cannot properly break down a fatty substance called Gb3. Over time, this fat collects in vital organs, especially the kidneys, and can cause long-term damage. This study is testing an investigational medicine called lucerastat in adult men aged 18 to 60 with Fabry disease who are not currently on treatment. It is an open-label trial, meaning everyone who takes part will receive lucerastat rather than a dummy drug (placebo). Participants will take lucerastat daily for 18 months and be monitored over 21 months in total. Doctors will check kidney health through regular clinic visits and two kidney biopsies—one at the start and one at the end. The goal is to see if lucerastat can clear the fatty buildup from kidney cells safely.

De un vistazo

Estado
Reclutamiento
Fase
FASE3
Patrocinador
Idorsia Pharmaceuticals Ltd.
Objetivo de inscripción
16
Inicio
01 Dic 2026
Estimación de finalización
15 Mar 2029

¿De qué trata este estudio?

Fabry disease is an inherited condition caused by a faulty gene. Because of this gene change, the body lacks an important enzyme needed to clear out a fatty substance called Gb3. Without this enzyme, Gb3 gradually builds up inside cells throughout the body, particularly in the kidneys, heart, and nervous system. Over time, this buildup can lead to organ damage, pain, and reduced kidney function.

Current treatments for Fabry disease exist in the UK, such as enzyme replacement therapy given by regular drips. However, researchers are studying lucerastat to see if an oral medicine can work differently by reducing the amount of fat the body produces in the first place. This trial focuses on whether lucerastat can reduce the amount of Gb3 stored in the kidneys of men who have not had recent treatment.

Because this is a Phase 3 study, doctors are looking closely at both how well the medicine works and whether it causes any unwanted side effects. The results could help scientists understand if lucerastat is a safe and helpful future treatment option for people living with Fabry disease.

Puntos clave

  • Tests an experimental daily tablet called lucerastat for adult men with Fabry disease.
  • Open to men aged 18 to 60 who are not currently receiving Fabry treatments.
  • Everyone on the trial receives the study drug (no dummy pills are used).
  • Requires daily medication for 18 months, 10 clinic visits, and two kidney biopsies.
  • Participation is voluntary, and existing approved NHS treatments are available.

¿Quién puede ser elegible?

This trial is for men aged between 18 and 60 who have a confirmed diagnosis of Fabry disease. To be eligible, you must have symptoms related to the condition, such as burning nerve pain, specific patterns on the surface of the eye, or small dark red spots on your skin. You must also be untreated, meaning you have not had an approved or trial treatment for Fabry disease in the past six months.

You will not be able to join if you have severe kidney problems, bleeding disorders, or other medical issues that make having a kidney biopsy unsafe. You must also have adequate blood counts and be able to safely pause any blood-thinning medicines if needed for the biopsy.

In the UK, approved treatments for Fabry disease are already available on the NHS. Before joining, doctors will discuss these existing options with you so you understand that lucerastat is still an experimental medicine undergoing testing.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. I am a man aged between 18 and 60.
  2. I have a confirmed diagnosis of Fabry disease.
  3. I have not received any treatment for Fabry disease in the last 6 months.
  4. I have symptoms such as nerve pain, dark skin spots, or eye changes linked to Fabry disease.
  5. I am willing and medically able to undergo two kidney biopsies.
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

Taking part in this study lasts for up to 21 months. You will take lucerastat tablets every day for 18 months. During the trial, you will visit the hospital clinic about 10 times for health checks, blood tests, and urine tests to monitor your kidneys and general wellbeing.

You will also have two kidney biopsies—one near the beginning of the study and one at the end. A biopsy is a minor procedure where doctors take a tiny sample of kidney tissue using a needle, allowing them to measure the exact amount of fat inside your kidney cells. The study team will support you throughout and monitor you closely for any side effects.

Riesgos y beneficios potenciales

Taking part may help reduce the buildup of fat in your kidneys, but because lucerastat is an experimental medicine, there is no guarantee it will improve your health. You may also experience unknown side effects from the drug. The kidney biopsies carry minor risks such as temporary pain, bruising, or bleeding. Taking part in research is entirely voluntary; you can choose to leave the study at any time without giving a reason, and your standard NHS care will not be affected.

Locations (16)

  • University of Alabama of Birmingham
    Código postal verificado
    Birmingham, United States· Aún no reclutando
  • UCSF Benioff Childens Hospital
    Código postal verificado
    Oakland, United States· Aún no reclutando
  • UF Health Center for Pediatric Neuromuscular and Rare Diseases
    Código postal verificado
    Gainesville, Estados Unidos· Aún no reclutando
  • Emory University School of Medicine
    Código postal verificado
    Atlanta, Estados Unidos· Aún no reclutando
  • Ann & Robert H. Lurie Childrens Hospital of Chicago
    Código postal verificado
    Chicago, Estados Unidos· Aún no reclutando
  • The University of Minnesota, Fairview Health
    Código postal verificado
    Minneapolis, United States· Aún no reclutando
  • Hospital of University Pennsylvania, Translational Medicine and Human Genetics
    Código postal verificado
    Filadelfia, Estados Unidos· Aún no reclutando
  • Dallas Nephrology Associates (DNA) - Dallas Landry Office Practice
    Código postal verificado
    Dallas, United States· Reclutamiento
  • VG Site pharmacy Dept 6 N-279
    Código postal verificado
    Halifax, Canadá· Aún no reclutando
  • CIUSSS-NIM/Hopital du sacre-Coeur de MontrealUnite de Recherche, Local C2030
    Código postal verificado
    Montreal, Canadá· Aún no reclutando
  • Centre Hospitalier Universitaire de Toulouse -Hôpital Purpan
    Código postal verificado
    Toulouse, France· Aún no reclutando
  • Hôpital Raymond-Poincaré
    Código postal verificado
    Garches, France· Aún no reclutando

Preguntas comunes

Will I receive a placebo (dummy pill)?

No. This is an open-label study, which means every participant receives the active trial medicine, lucerastat.

What is a kidney biopsy?

A kidney biopsy is a common medical test where a doctor numbs the skin and uses a thin needle to remove a tiny piece of kidney tissue for examination under a microscope.

Why is this trial only open to men?

Fabry disease is linked to the X chromosome, meaning men generally have more severe enzyme deficiencies and clearer kidney fat buildup, making it easier for scientists to measure if the medicine works.

Can I leave the trial if I change my mind?

Yes. You are free to stop taking part at any point. Your normal healthcare and relationship with your doctors will continue as normal.

Does taking part cost anything?

No, the trial medicine and all tests are provided free of charge, and travel expenses to clinic visits are usually reimbursed.

Cómo obtener más información

Clinical Trial Information USA

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "A Study to Learn How Well Lucerastat Works and How Safe it i…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.